Coal tar soap label sets out a narrow topical role for psoriasis and dandruff
DailyMed’s updated label for coal tar soap places the product in a familiar but tightly defined dermatologic niche: topical symptom control for psoriasis and dandruff. The formulation carries a coal tar 2.13% active ingredient concentration and is packaged as a human OTC drug under the DERMABON PSORIASIS AND DANDRUFF name. Its status matters because coal tar remains one of the oldest antipruritic and keratolytic approaches in dermatology, used when scaling, flaking, and inflammatory turnover need to be reduced without moving immediately to prescription therapy.
The label describes a product intended for external use on affected areas in place of regular soap. That simple instruction reflects the way coal tar has traditionally been deployed: not as a systemic intervention, but as a local, repeated exposure therapy that interacts with the epidermis and scalp surface where psoriatic plaques and dandruff are most active.
The formulation combines coal tar with emollient and preservative components
Beyond the active ingredient, the bar includes a familiar supporting matrix of inactive substances: sodium borate, alcohol, petrolatum, glycerin, glyceryl monostearate, alpha-tocopherol, water, methylparaben, lanolin, sodium hypochlorite, and stearic acid. In practical terms, those ingredients shape the bar’s texture, cleansing behavior, moisturizing profile, and shelf stability. For patients with scaly inflammatory skin disease, the vehicle can matter almost as much as the active ingredient, because overly drying soap bases can intensify irritation and undermine adherence.
Coal tar itself is the centerpiece. Dermatology has long relied on this class of products for their effect on excessive epidermal proliferation and scaling. In psoriasis, where accelerated keratinocyte turnover drives thick plaques and surface scale, a tar-based cleanser aims to soften the surface burden and calm the visible roughness that drives discomfort and self-consciousness. In dandruff, the same topical logic applies to the scalp: reduce visible flaking, loosen adherent scale, and limit the cycle of irritation that feeds further shedding.
Sun sensitivity and eye exposure warnings are central to safe use
The warning language is clinically direct. The product is for external use only, and eye contact should be avoided. If the soap reaches the eyes, the label advises thorough rinsing with water. The label also warns that skin may become more prone to sunburn for up to 24 hours after application, which gives coal tar a distinctly practical safety issue in daily life: a patient who uses the product and then spends time outdoors may be more vulnerable to phototoxic irritation or sunburn-like reactions.
One sentence in the label carries particular bedside weight: use caution in exposing skin to sunlight after applying this product.
That instruction is not cosmetic. Coal tar products can increase photosensitivity, and the simplest risk-reduction strategy is behavioral rather than pharmacologic: avoid unnecessary sunlight exposure after use, and recognize that a cleanser intended to improve scale can still irritate skin if the exposure pattern is careless.
Prolonged unsupervised use and combination therapy are discouraged
The label discourages prolonged use without consulting a doctor. It also advises against combining the product with other forms of psoriasis therapy, including ultraviolet radiation or prescription drugs, unless a clinician directs it. In real-world dermatology, that caution is important because psoriasis care often involves layered treatment plans, and overlapping exposures can increase irritation or obscure whether the skin is improving because of one therapy or another.
If the condition covers a large area of the body, consultation with a doctor is advised before use. The warning fits the basic pharmacologic reality of topical coal tar: even though this is an OTC bar soap, a larger treated surface increases the chance of irritation, poor tolerability, or a need for a different treatment strategy altogether. A product that may be reasonable for a limited plaque or localized scalp flaking is not automatically a good fit for widespread disease.
Packaging, category, and regulatory details place the product in OTC monograph use
The label identifies the product as a human OTC drug with no DEA schedule, marketed under NDC 87984-102-01 in a 90 g package. The marketing category is an OTC monograph drug citation, indicating use within an established nonprescription framework rather than through an individualized prescription pathway. The registrant and manufacturer are listed as Belleza Natural Ohnbrand, S.A. de C.V., and the label update is dated October 14, 2026.
For clinicians and patients, those administrative details do more than fill a regulatory record. They define how the product enters care: as a readily available topical option with modest complexity, clear warnings, and a narrow therapeutic lane. Coal tar soaps remain part of dermatologic self-care because they are simple to use and biologically plausible for scale-heavy inflammatory disease, yet their benefits depend on disciplined use and respect for the product’s irritant and photosensitizing potential.
The label does not claim systemic efficacy, does not describe comparative trials, and does not present outcome data. It functions instead as a concise safety and use document for a classic topical therapy whose value is limited to the skin it touches.